Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SUTENT vs ELLENCE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.
ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.
Gastrointestinal stromal tumor (GIST) after disease progression on or intolerance to imatinib mesylate,Advanced renal cell carcinoma (RCC),Adjuvant treatment of adult patients at high risk of recurrent RCC after nephrectomy,Progressive, well-differentiated pancreatic neuroendocrine tumors (p NET) in patients with unresectable locally advanced or metastatic disease
Adjuvant therapy in patients with axillary node-positive breast cancer,Treatment of metastatic breast cancer,Off-label: treatment of ovarian cancer, gastric cancer, small cell lung cancer, and soft tissue sarcoma
50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).
60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.
Terminal elimination half-life of sunitinib is 40-60 hours; for its primary active metabolite (SU12662) it is 80-110 hours. Steady-state achieved by day 14.
Terminal elimination half-life is approximately 20-40 hours (mean ~30 hours). This supports a 3-week dosing interval to allow for recovery from myelosuppression.
Primarily metabolized by CYP3A4; the major metabolite (N-desethyl sunitinib) is also active and is further metabolized by CYP3A4.
Primarily hepatic metabolism via aldoketoreductases and conjugation; also metabolized by glucuronidation and cytochrome P450 (CYP) enzymes, including CYP2B4 and CYP3A4.
Renal: 16% of total radioactivity; Fecal: ~70% of total radioactivity (primarily as unchanged parent and metabolites).
Primarily hepatobiliary excretion: ~40-50% of dose excreted as unchanged drug and metabolites in bile and feces. Renal excretion accounts for <10% (mostly as metabolites).
95% bound to human plasma proteins (albumin and alpha-1-acid glycoprotein).
Approximately 77% bound to plasma proteins, primarily albumin.
Apparent volume of distribution (Vd/F) is approximately 2230 L (enterprise, not weight-adjusted). The Vd is large, indicating extensive extravascular distribution.
Mean volume of distribution is 13-34 L/kg (average ~21 L/kg), indicating extensive tissue distribution and binding.
Oral bioavailability is approximately 40% (range 30-50%).
IV only; oral bioavailability is negligible (<5%) due to extensive first-pass metabolism. Not administered orally.
No adjustment for mild-to-moderate renal impairment (Cr Cl ≥30 m L/min); avoid use in severe impairment (Cr Cl <30 m L/min) due to lack of data.
No specific GFR-based dose adjustments required; caution in severe renal impairment (Cr Cl <10 m L/min) with potential increased toxicity.
Child-Pugh Class A: 50 mg daily; Class B: reduce to 37.5 mg daily; Class C: not recommended.
Child-Pugh A: reduce dose by 25%; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated or use at 50% reduction with caution.
Not approved for pediatric use; no established weight-based dosing.
75-100 mg/m2 IV on Day 1 of 21-day cycles or 20-30 mg/m2 IV daily for 3 days every 28 days.
No specific dose adjustment; monitor renal function and blood pressure more frequently due to increased sensitivity to adverse effects.
No specific dose adjustment; consider increased susceptibility to myelosuppression and cardiotoxicity; monitor left ventricular ejection fraction.
Hepatotoxicity: Severe, sometimes fatal hepatotoxicity has been observed. Monitor liver function tests before and during treatment. Interrupt or discontinue SUTENT and manage as appropriate.
Myocardial toxicity, including potentially fatal congestive heart failure, especially with cumulative doses >900 mg/m²; secondary acute myeloid leukemia (AML) or myelodysplastic syndrome (MDS); extravasation leading to severe tissue necrosis; severe myelosuppression.
Hepatotoxicity: Monitor liver function tests before and during therapy; interrupt or discontinue for severe hepatotoxicity.,Cardiovascular events: Hypertension, QT prolongation, left ventricular dysfunction, including heart failure; monitor blood pressure and cardiac function.,Hemorrhage: Severe, sometimes fatal hemorrhagic events; monitor for signs and symptoms.,Thyroid dysfunction: Monitor thyroid function; manage with thyroid hormone replacement as needed.,Adrenal insufficiency: Reported; monitor for symptoms.,Proteinuria: Monitor urine protein; discontinue for nephrotic syndrome.,Wound healing complications: Withhold therapy for at least 24 days prior to elective surgery.,Reversible posterior leukoencephalopathy syndrome (RPLS): Discontinue if signs/symptoms occur.,Thrombotic microangiopathy (TMA): Reported; discontinue if TMA occurs.
Cardiotoxicity (cumulative dose-dependent), myelosuppression, secondary leukemia, extravasation, hepatotoxicity, renal impairment, immunosuppression, tumor lysis syndrome, and fetal harm.
None known.
Severe hepatic impairment (Child-Pugh class C), severe renal impairment (Cr Cl <30 m L/min), baseline neutrophil count <1500 cells/mm³, severe cardiac dysfunction, hypersensitivity to epirubicin or other anthracyclines.
Avoid grapefruit and grapefruit juice during treatment. St. John's wort may reduce efficacy. No other significant interactions.
Avoid grapefruit and grapefruit juice during treatment as they may affect drug metabolism. No other specific food interactions known.
Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth restriction, oligohydramnios, and preterm delivery due to antiangiogenic effects. Avoid use in pregnancy.
Pregnancy Category D. First trimester: High risk of teratogenicity including cardiac anomalies, skeletal defects, and fetal demise. Second and third trimesters: Risk of fetal growth restriction, preterm birth, and neonatal myelosuppression. Avoid use unless absolutely necessary.
No human data available; M/P ratio unknown. Sunitinib and its metabolites are excreted in rat milk. Due to potential for serious adverse reactions in nursing infants, breastfeeding is contraindicated during therapy and for at least 4 weeks after the last dose.
Contraindicated due to potential transfer into breast milk (M/P ratio not available). Theoretical risk of severe adverse effects in infants including bone marrow suppression and cardiotoxicity. Discontinue nursing or drug.
No pharmacokinetic data in pregnancy; dose adjustments are not established. Given teratogenicity, use is not recommended. If unavoidable, consider reduced dose (e.g., 37.5 mg daily) with close monitoring, but safety and efficacy are not validated.
No established dose adjustments; avoid use if possible. Pharmacokinetic changes include increased volume of distribution and clearance, but insufficient data to recommend dose modification. Use reduced doses if unavoidable, guided by toxicity monitoring.
Monitor for hypertension and proteinuria; manage with antihypertensives. Check thyroid function before and during therapy due to risk of hypothyroidism. Monitor liver enzymes and cardiac function, especially in patients with pre-existing conditions. Dose adjustments needed for hepatic impairment (Child-Pugh Class C).
Ellence (epirubicin) is an anthracycline chemotherapeutic agent. It is a vesicant; extravasation can cause severe tissue necrosis. Administer via a freely flowing IV line. Premedicate with antiemetics. Monitor for cardiotoxicity, which is dose-dependent and may be cumulative. Total lifetime dose should not exceed 900-1000 mg/m². Assess cardiac function (LVEF) before and during treatment. Urine may turn red for 1-2 days after administration. Avoid live vaccines.
Take with or without food, but avoid grapefruit juice.,Report any signs of bleeding, unusual bruising, or fatigue.,Monitor blood pressure regularly and report high readings.,Watch for changes in skin color (yellowing or darkening) or nail changes.,Use effective contraception during treatment and for at least 4 weeks after stopping.,Avoid sun exposure; use sunscreen and protective clothing.
Ellence can cause severe nausea and vomiting; take antiemetics as prescribed.,Report any pain, redness, or swelling at the injection site immediately.,Urine may appear red for 1-2 days after treatment; this is normal.,Use effective contraception during and for at least 6 months after treatment.,Avoid live vaccines (e.g., MMR, varicella) while on this medication.,Report signs of infection (fever, chills), unusual bleeding or bruising, shortness of breath, or chest pain.,Do not breastfeed while taking Ellence.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SUTENT vs ELLENCE, answered by our medical review team.
SUTENT is a Tyrosine Kinase Inhibitor Antineoplastic that works by Sunitinib is a multi-targeted receptor tyrosine kinase inhibitor that inhibits platelet-derived growth factor receptors (PDGFR-α and PDGFR-β), vascular endothelial growth factor receptors (VEGFR-1, VEGFR-2, VEGFR-3), stem cell factor receptor (c-KIT), FMS-like tyrosine kinase-3 (FLT3), colony-stimulating factor 1 receptor (CSF-1R), and the glial cell line-derived neurotrophic factor receptor (RET). It inhibits angiogenesis and tumor cell proliferation.. ELLENCE is a Anthracycline Antineoplastic that works by ELLENCE (epirubicin) is an anthracycline cytotoxic antibiotic. It intercalates between DNA base pairs, inhibits topoisomerase II activity, and generates free radicals, leading to DNA damage and cell death.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SUTENT and ELLENCE depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SUTENT is: 50 mg orally once daily for 4 weeks, followed by 2 weeks off (schedule 4/2).. The standard adult dose of ELLENCE is: 60-120 mg/m2 IV bolus or slow infusion on Day 1 every 21-28 days; or 20-30 mg/m2 IV daily for 3 days repeated every 28 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SUTENT and ELLENCE in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SUTENT is classified as Category C. Pregnancy category D. First trimester: high risk of embryofetal toxicity including skeletal and cardiovascular malformations. Second and third trimesters: risk of fetal growth rest. ELLENCE is classified as Category C. Pregnancy Category D. First trimester: High risk of teratogenicity including cardiac anomalies, skeletal defects, and fetal demise. Second and third trimesters: Risk of fetal growt. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.